To include your compound in the COVID-19 Resource Center, submit it here.

Verastem submits NDA to FDA for duvelisib

Verastem Inc. (NASDAQ:VSTM) submitted an NDA to FDA for duvelisib (IPI-145) to treat relapsed or refractory chronic lymphocytic

Read the full 189 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE